Table 3. Association of NLRP3 single nucleotide polymorphism with biopsy proven acute rejection.
| Gene rs number | Genotype | Donor |
Recipient |
||
|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | ||
| Biopsy-proven acute rejection | |||||
| NLRP3 (GOF) rs35829419 | A/A (ref)A/a + a/a | 1.001.48 (1.12–1.96) | 0.006 | 1.000.93 (0.68–1.26) | 0.62 |
| NLRP3 (LOF) rs6672995 | A/A (ref)A/a and a/a | 1.001.11 (0.90–1.36) | 0.32 | 1.000.72 (0.58–0.91) | 0.005 |
| OR2B11/NLRP3 (LOF) rs4353135 | A/A (ref)A/a + a/a | 1.001.06 (0.87–1.28) | 0.58 | 1.001.04 (0.96–1.25) | 0.70 |
| Biopsy-proven acute rejection, ≤12 months after transplantation (N = 391) | |||||
| NLRP3 (GOF) rs35829419 | A/A (ref)A/a + a/a | 1.001.54 (1.15–2.05) | 0.003 | 1.000.88 (0.64–1.22) | 0.45 |
| NLRP3 (LOF) rs6672995 | A/A (ref)A/a + a/a | 1.001.09 (0.88–1.35) | 0.42 | 1.000.68 (0.54–0.87) | 0.002 |
| OR2B11/NLRP3 (LOF) rs4353135 | A/A (ref)A/a + a/a | 1.001.06 (0.87–1.30) | 0.56 | 1.001.06 (0.87–1.29) | 0.58 |
| Biopsy-proven acute rejection, >12 months after transplantation (N = 851) | |||||
| NLRP3 (GOF) rs35829419 | A/A (ref)A/a + a/a | 1.000.82 (0.25–2.67) | 0.74 | 1.001.30 (0.54–3.09) | 0.56 |
| NLRP3 (LOF) rs6672995 | A/A (ref)A/a + a/a | 1.001.24 (0.64–2.41) | 0.52 | 1.001.16 (0.60–2.25) | 0.66 |
| OR2B11/NLRP3 (LOF) rs4353135 | A/A (ref)A/a + a/a | 1.000.93 (0.50–1.73) | 0.82 | 1.000.83 (0.44–1.54) | 0.55 |
Homozygous dominant (A/A) is considered reference group (ref) and compared to heterozygous + homozygous recessive (A/a + a/a). GOF = gain of function, LOF = loss of function, HR = hazard risk, CI = confidence interval.